Under the deal, CoreRx will integrate its expertise in problem-solving and formulation/processing of small molecules with Viropro’s specialization in the development and manufacturing of biopharmaceutical drugs to provide both companies’ existing and potential clients with diverse product pipelines.
Viropro interim CEO and chairperson Cynthia Tsai said with the agreement, the company has expanded its commitment to deliver solutions to advance new medicines.
"It will also leverage Viropro’s expertise to provide clients with optimized solutions to their biopharmaceutical development challenges," Tsai added.
CoreRx CEO Todd Daviau said the company has been working to meet the challenges of drug delivery and enhance the performance of clients’ drugs.
"By addressing the needs of clients in biosimilar and large molecule development, CoreRx will continue to play a role in the development of drug candidates and the diversification of their pipelines," Daviau added.